1. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)
- Author
-
Tomio Inoue, Yoshihide Nakamura, Asami Kitaoka, Hideharu Ikebuchi, Sachiko Yanagida, Takahiro Yamada, Nobutaka Nakamura, Kiyotaka Kojima, Seigo Kinuya, Makoto Hosono, Hiroyasu Sugano, and Jun Hatazawa
- Subjects
medicine.medical_specialty ,Health Personnel ,Lu-177-DOTA-TATE ,Neuroendocrine tumors ,Lutetium ,Radionuclide therapy ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,chemistry.chemical_compound ,Manuals as Topic ,0302 clinical medicine ,Radiation Protection ,Neuroendocrine tumor ,Japan ,Report ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,DOTA-TATE ,business.industry ,General Medicine ,Guideline ,medicine.disease ,Somatostatin Analogue ,Neuroendocrine Tumors ,chemistry ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Christian ministry ,Radiation protection ,Nuclear Medicine ,Radiopharmaceuticals ,Safety ,business - Abstract
Here we present the guideline for the treatment of neuroendocrine tumors using Lu-177-DOTA-TATE on the basis of radiation safety aspects in Japan. This guideline was prepared by a study supported by Ministry of Health, Labour, and Welfare, and approved by Japanese Society of Nuclear Medicine. Lu-177-DOTA-TATE treatment in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown in this guideline are considered internationally useful as well. Only the original Japanese version is the formal document.
- Published
- 2018